BW-20829
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 for Elevated Lp(a)
Argo Biopharma; BW-20829; Phase 2b trial; siRNA; Lp(a); Novartis; cardiovascular disease
Actionable Insights Powered by AI
Argo Biopharma; BW-20829; Phase 2b trial; siRNA; Lp(a); Novartis; cardiovascular disease